Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

<div>Flow cytometric analysis on the immune function of patients with poor prognosis in the treatment group (it represents the change of CD4/CD8 ratio in patients with poor therapeutic efficacy during treatment, with the ratio getting lower and lower. Three continuous flow charts of typical patients were used here).</div>

Journal of Oncology

fig8

Figure 8

Figure 8: Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer 

Figure 8 | Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer 